Andreev et al. hypothesized that because HER2 has limited internalization, if coupled to the prolactin receptor (PRLR) that is known to undergo rapid internalization [121], then anti-HER2 antibodies can have more efficient anti-tumor activities [75]. The gene discussed is ERBB2; the disease is neoplasm.